On the other hand, in the neoadjuvant setting, only a trend toward an inferior OS for patients with a PIK3CA mutated tumor was reported in the Gepar experience [18], but data on survival from the pooled analysis by Loibl et al [44] could not allow to draw definite conclusions. Here, PIK3CA is linked to neoplasm.